Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 355 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than... April 11, 2024 Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... August 4, 2021 World Cancer Day 2023: where does the UK stand? February 3, 2023 Join the Great American Smokeout for a Healthier Tomorrow November 14, 2023 Load more HOT NEWS Delivering Palliative Care by Telehealth Meets the Needs of People with... Mom Battling Breast Cancer And Daughter With Alopecia Pose Together To... Sound Waves Can Target Lymph Nodes And Help Kill Breast Cancer... Sustainability a major focus of our 17th year partnering with TK...
